T ransplantation of the vascularized pancreas is the only proven long-term means of establishing normoglycemia in type 1 patients with diabetes. At our center we have focused on Simultaneous pancreas-kidney (SPK) transplantation since 1985, and present the largest SPK experience in the world. To be widely accepted, SPK transplantation has to fulfill the following criteria: (1) a life expectancy which is equivalent or even better compared with patients who do not receive a transplant; and (2) an enhancement of the patient's quality of life. A clear-cut demonstration that pancreas transplantation reduces or even reverses secondary diabetic complications would strengthen the indications for SPK; however, at this point, no prospective randomized trials have been conducted, and the majority of observations come from small single-center studies not powered or sufficiently controlled to make a definitive statement.
The first pancreas transplant was performed on December 17, 1966, by Kelly et al. This transplant was a duct-ligated segmental graft implanted simultaneously with a kidney from a deceased donor. This patient experienced multiple complications but was insulin independent for 6 days. 1 A second pancreas transplant was performed on December 31, 1966 , as a whole pancreatic duodenal allograft. In this case, the donor duodenum was brought out as a stoma to provide drainage of exocrine secretions. 1 In the fifth case, a pancreaticoduodenal transplant with enteric drainage via a Rouxen-Y loop was performed. This technique is very similar-in fact, in principle almost identical-to the enteric drainage technique used in current practice. 2 Unfortunately, imperfect immunosuppression and lack of adequate graft preservation techniques yielded poor results, with only 6 of 25 patients transplanted worldwide surviving more than 1 year. 3 Only 1 patient remained insulin independent for a prolonged period of time.
Surgeons attempted to find a solution by experimenting with different surgical techniques, including segmental duct ligated grafts, whole pancreaticoduodenal transplants with the spleen attached, duct injection, and segmental grafts with the main pancreatic duct anastomosed to the ureter. 4 All techniques were eventually abandoned due to complications of the techniques. Transplant outcomes were also poor. In 1980, the International Pancreas Transplant Registry (available at: www.iptr.umn.edu), founded and carefully maintained by Dr. David E. R. Sutherland, reported a 1-year graft survival of 21% and a 1-year mortality of 39% after pancreas transplantation. 5 Our team at the University of Wisconsin searched for a new technique for exocrine drainage. We first devised the bladder drainage technique in dogs, 6 and a year later reported a small group of patients with relatively good success. 7 The first group of patients received segmental grafts, but in 1985 whole pancreaticoduodenal grafts were used. The first series reported included 390 patients with bladder drainage. 8 Recognizing the morbidity associated with bladder drainage, and having introduced mycophenolate mofetil (CellCept, Roche Laboratories, Nutley, NJ), 9 we decided in 1995 to switch to enteric drainage. In December 3, 2007, we performed 610 consecutive SPKs using this technique.
PATIENTS AND METHODS

Patients
Between December 18, 1985 and December 3, 2007 , 1000 consecutive SPK transplants were performed at the University of Wisconsin Transplant Center. Bladder drainage was used in 390 patients and enteric drainage in 610 patients. Retrospective analysis of outcomes for this study was conducted after approval by the University of Wisconsin Health Sciences Institutional Review Board.
Of the 1000 patients described in this study, all were diagnosed with insulin-dependent diabetes. In the first era of our program, patients with a history of cardiac interventions (bypass graft, angioplasty, stent) or peripheral vascular problems (amputation, bypass graft) were excluded. With growing experience, however, the indications changed, and now we include all patients cleared by our designated transplant cardiologist and multidisciplinary team. In the first 15 years of the program, patients were placed on the waiting list if they had a negative nuclear stress test in the absence of physical symptoms. In the past decade, we have requested coronary angiography in most patients over 35 years of age. In addition, the majority of patients undergo an evaluation of their iliac arteries, usually by iliac angiogram or noncontrast enhanced CT scan, to determine the extent of atherosclerotic disease.
Patient age ranged from 11 to 55 years. A total of 387 patients were transplanted before the initiation of dialysis. Details of recipient characteristics are shown in Table 1 . At our center, the number of patients transplanted pre-emptively is higher than the national average (Scientific Registry of Transplant Recipients 2008 Report, available at: www.ustransplant.org). Cardiac interventions before transplantation are shown in Table 2 .
Surgical Technique
Preparation of the pancreaticoduodenal allograft before implantation is performed in ice-cold UW solution (ViaSpan, Bristol Myers Squibb, Garden City, NY). The important points include shortening of the duodenal segment and oversewing the proximal and distal staple lines. Splenectomy is performed and neurolymphatic tissue in the area of the superior mesenteric artery and splenic artery is carefully removed. The portal vein is lengthened by ligating and dividing smaller venous branches. Arterial reconstruction is routinely performed with a donor iliac artery Y graft as described earlier. 8 With the exception of the first case, all transplants were performed through a midline incision. The pancreas was always transplanted on the right side, with the venous anastomosis to the common iliac vein and the arterial anastomosis to the common iliac artery. The kidney was always placed on the left, again with the vascular anastomosis to the common iliac vein and the common iliac artery.
Details of the bladder drainage technique were described previously. 8 In the first 12 cases we used a duodenal button technique ( Fig. 1) , implanting a round segment of duodenum into the bladder. After Nghiem and Corry described the duodenal segment technique 10 ( Fig. 2) , we switched to this drainage modality. After 390 bladder-drained SPKs, we began using enteric drainage as previously described. 8 In 246 cases, the head of the pancreas was directed caudal and in the remainder cephalad. The implant site in enteric drainage is variable and usually 20 to 60 cm distal to the ligament of Treitz (Fig. 3) . An important technical aspect of our program is that, with the exception of aspirin (Bayer Corporation, Pittsburgh, PA), we do not use anticoagulation intraoperatively or postoperatively. A small series of patients received Plavix (clopidogrel bisulfate, BristolMyers Squibb/Sanofi Pharmaceuticals Partnership, Bridgewater, NJ), and will be separately reported. We have never used a portal venous extension graft despite the fact that 71% of grafts were procured simultaneously with a liver. Beginning in 2004, we abandoned the use of a nasogastric tube and have now performed more than 150 transplants without nasogastric drainage.
11
Donor Operative Procedure, Organ Preservation, and Donor Characteristics
The details of the organ retrieval have been described previously. 8, 10 Until the description of combined liver-pancreas procurement by Marsh et al, 12 either the pancreas or liver were procured. Later at our center, in 71% of cases, the pancreas was used whenever the liver was found to be usable. 13 In the early period, a complete dissection of the liver and pancreas with in situ division of the portal vein was performed. In recent years, pancreas and liver have been removed en bloc. All pancreata were preserved in UW solution with in situ flushing using 1 to 2 L of UW solution. Detailed donor characteristics are shown in FIGURE 2. Duodenal segment technique. 
Enteric Conversion
Enteric conversion was performed for a variety of indications as outlined in the Results section ( Table 4 ). The operation was performed using the previously placed midline incision. In most cases it was possible to pass a finger behind the bladder and encircle the duodenal segment. The bladder-duodenal anastomosis was then opened by cutting in a circular fashion about 2 to 3 mm from the duodenum into the bladder. The bladder was then closed in 2 layers with absorbable monofilament running suture. The duodenal segment was implanted 40 to 60 cm proximal to the ileocecal valve in an side-to-side fashion using 2 layers (Fig. 4) . In cases where the duodenal segment was atrophic or friable, a Roux-en-Y loop was created to protect the anastomosis.
Retransplantation
One hundred thirteen recipients with a failed kidney transplant underwent retransplantation, 64 with a living related or unrelated kidney and 42 with a deceased donor kidney. If a live donor was available, this was the preferred option. The donor type for retransplantation is shown in Table 5 . Kidney retransplantation was performed using the previous midline incision. Dissection of the original renal vein and artery was possible in the majority of cases; however, rarely, dense scar tissue surrounding the renal hilum made the dissection impossible. In these cases the entire pedicle was clamped and the kidney was removed. The vessels were later dissected with proximal and distal arterial and venous control. Whenever possible, the previous vein and artery were used for reanastomosis. Alternatively, any available segment of external iliac vein or artery on either side was used. The results of kidney retransplantation are shown in Figure 5 . 
Statistical Analysis
Continuous variables were summarized by reporting means and standard deviations and categorical variables were summarized by reporting percentages. Event rates were estimated using the methods of Kaplan and Meier and compared between groups using a log-rank test. P Ͻ 0.05 was considered as significant. All analyses were performed using SAS statistical software, SAS Institute Inc, Cary, NC.
RESULTS
Survival
Patient survival for SPK recipients is shown in Figure 6 and compared with survival for diabetic recipients of living donor and deceased donor kidney transplants at our center. In addition, the survival of type 1 patients with diabetes on dialysis is depicted. The 5-, 10-, and 20-year patient survival for SPK recipients was 89%, 80%, and 58%, respectively.
Kidney graft survival for SPK recipients is shown in Figure 7 . The overall 5-, 10-, and 20-year kidney graft survival was 80%, 63%, and 38%, respectively. Peculiarly, there was no difference in kidney graft survival comparing bladder drained versus enterically drained pancreas transplants. This is unexpected given the high frequency of rejection and infectious complications that occurred in the bladder-drained era and improved immunosuppression (mycophenolate and tacrolimus) in the enteric drainage era.
The pancreas transplant survival is shown in Figure 8 . Again, there was no difference in pancreas allograft survival between enterically drained and bladder-drained allografts. The overall 5-, 10-, and 20-year pancreas graft survival was 76%, 63%, and 36%, respectively. More than 35% of patients remain insulin independent after 20 years and are now available for long-term studies. With the exception of an initially rapid graft loss rate related to technical failures for the pancreas and acute rejection for the kidney, graft losses remained gradual and constant over the observation period.
Bladder Versus Enteric Drainage
Despite the lack of survival differences, the quality of life with bladder drainage is inferior to that with enteric drainage. Shortand long-term complications of bladder drainage include metabolic acidosis, a high incidence of urinary tract infections, 8 hematuria, urethritis, and urethral disruption, and dysuria. Bladder drainage of pancreatic exocrine secretions clearly leads to more urinary tract infections, as shown in Figure 9 . 17 In an attempt to restore quality of life and correct serious urinary tract complications as well as intractable metabolic acidosis, more than half of the surviving patients underwent conversion to enteric drainage. Within 5 years after transplantation, approximately 30% of the total number of surviving patients underwent enteric conversion and within 15 years approximately 50% had undergone conversion (Fig. 10) .
In a few patients, conversion was indicated as late as 20 years after transplantation. Our experience revealed that patients transplanted with the duodenal button technique cannot be converted due to dense adhesions to the head of the pancreas. We also learned that when conversion is performed late after transplantation, there is a much higher leak rate due to the increased friability of the duodenal segment. We now recommend routine use of a Roux-en-Y loop in all late conversions on the basis of this experience. Indications for enteric conversion are shown in Table 4 .
Surgical Complications
Surgical complications after SPK transplantation have been greatly reduced over the years. In our center, avoidance of systemic anticoagulation with heparin or dextran has resulted in a low rate of bleeding requiring re-exploration while maintaining a very low rate of pancreatic graft thrombosis. 18 We also believe that not using a venous interposition graft to extend the portal vein is beneficial in reducing the risk of pancreas graft thrombosis. Nevertheless, overall complications, including urinary tract infection, are high after SPK transplantation (Fig. 11) , with a trend toward a higher early complication rate associated with enteric drainage (Fig. 12) .
Surgical complications related to SPK transplantation which required reoperation within 30 days, within 1 year, and after 1 year are shown in Table 6 . More complications requiring reoperation are seen in the early postoperative period in the enterically drained recipients than in bladder-drained recipients; however, a greater percentage of patients require late (Ͼ1 year) reoperation for surgical complications in the bladder drainage group, owing to the need for enteric conversion in a significant fraction of these patients. 
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Induction Therapy With Campath-1H
Campath-1H, a monoclonal antibody discovered by Cobold and Waldman, was touted as a promising induction agent. Magliocca et al, from our center presented a large series in greater detail than is presented here. 15 The early analysis showed a trend for improved patient survival (Fig. 13) , but a subsequent analysis of the benefits of alemtuzumab induction did not show any survival advantage over induction with IL-2 receptor antibodies. 19 While infections were similar overall, 15 there was a statistically higher incidence of cytomegalovirus infection and viremia in the alemtuzumab-treated group. It is of interest that we did not see a high incidence of humoral rejections although some acute and chronic antibody mediated rejection episodes were observed. 20 We attribute this to the fact that the majority of patients were first transplants and had a low level of sensitization. Overall, the consensus was that Campath-1H does not offer a substantial benefit, and we returned to basiliximab induction during the most recent era of our program. 
Human Leukocyte Antigen Matching and SPK Transplantation
The influence of human leukocyte antigen (HLA) matching on the long-term outcome of kidney transplantation has been a matter of intensive analysis over the past 30 years. Both Opelz et al 21 and Terasaki et al 22 have published manuscripts using large databases to demonstrate the influence of matching on short-and long-term graft survival.
There is general agreement that 6-antigen matched allografts indeed have better graft survival at a statistically significant level in kidney transplantation alone. Intuitively, it would seem that SPK transplantation would follow the same rules. It was for this reason that the United Network for Organ Sharing mandated sharing for 6-antigen matched SPKs, without strong supporting data. However, there is no evidence that HLA matching is associated with better graft survival in SPK transplantation.
In our own analysis of 500 SPKs, we did not see any matching effect. 8 This was confirmed by the recent analysis of 1000 SPKs. As Figures 14 to 16 show, patient, kidney, and pancreas survival have no significant correlation with HLA-matching.
Donation After Cardiac Death
Donation after cardiac death (DCD) continues to be a viable method to expand the organ procurement pool for kidney, liver, lung, and pancreas transplantation. We have routinely accepted selected DCD donors for SPK and solitary pancreas transplantation at our center if warm ischemia times are less than 45 minutes and otherwise the donor meets criteria for pancreas donation. Of all SPK transplants, 8.6% were recovered from DCD donors. We compared outcomes between donation after brain death (DBD) and DCD donors.
Pancreas function and outcomes are indistinguishable between the 2 modes of procurement. Ten-year patient survival between SPK recipients from DBD and DCD donors is similar (80% vs. 84%, respectively; P ϭ 0.97). Pancreas graft survival at 5 years is 76% in the DBD group compared with 75% in the DCD group (P ϭ 0.57), and 64% and 60%, respectively, at 10 years. Acute cellular rejection was seen in 27% at 10 years for pancreata in the DBD group compared with 20% for the DCD cohort. Both fasting blood glucose and hemoglobin A1C levels were very similar in the 2 groups when compared at either the 60 month or 120 month time point. Within the DCD SPK group, the outcomes were identical between pancreata with a warm ischemia time above and below 30 minutes.
Although DCD kidneys exhibit a higher rate of delayed graft function, there appears to be no significant impact on long-term outcomes. Delayed graft function and lower glomerular filtration rate (GFR) at 7 days posttransplant occurs more frequently in DCD kidneys (P ϭ 0.001 for both), but GFR was equivalent at first month comparing the DBD and DCD groups, and remained similar for the remainder of the follow-up period. Occurrence of acute cellular rejection of the kidney was not significantly different in the 2 groups with rates of 52% and 54% at 5 and 10 years, respectively, in the DBD group compared with 39% and 39% in the DCD cohort. Kidney function as measured by creatinine and GFR at 10 years was nearly identical in the 2 groups, P ϭ 0.89 and P ϭ 0.78, respectively.
Cause of Death
A major cause of death after SPK in this series was due to cardiovascular events, usually myocardial infarction confirmed by autopsy or by clinical presentation and laboratory diagnosis ( Table  7) . This prompted us to adopt stricter preoperative screening criteria in the recent era of our program, with 72% of patients undergoing coronary angiography between 2005 and 2007.
Death from infections were either systemic or surgical in nature often originating from an anastomotic leak or related to infected peripancreatic tissue. A large number of deaths (n ϭ 57) occurred in a setting where an accurate diagnosis was not possible and/or autopsy was declined or inconclusive.
Technical Complications and Causes of Graft Loss
In the bladder-drained series, the most common technical complication was a leak at the pancreaticocystostomy. Surgical repair was rarely successful; however, conservative treatment with Foley drainage resulted in the closure of some leaks. On occasion, the diagnosis of a leak was difficult, and several detection methods have been described. Eckhoff et al from our center reported on the high detection yield using nuclear imaging techniques. 23 Enteric leaks could be repaired with a higher success rate, frequently using Roux-en-Y diversion to protect the repaired anastomosis. The total number of leaks is shown in Table 8 .
The major reasons for pancreatic graft loss, comparing enteric with bladder drainage, are shown in Table 9 and the reasons for kidney graft loss are shown in Table 10 . In both groups, death with a function was the leading cause of pancreatic graft loss (Table 9) , followed by acute and chronic rejection. Bleeding as a cause of graft loss was higher in the enteric group and usually associated with a leak followed by an anastomotic arterial aneurysm. Graft thrombosis was a very infrequent cause of graft loss despite the fact that no systemic anticoagulation was used.
DISCUSSION
The uniqueness of this large series of SPKs lies in the fact that nearly all operations were performed by only 3 surgeons (H.W.S., . Therefore, management strategies, including operative techniques, were standardized, and whenever changes were made, the entire group adopted them. Clearly, the major lesson to be learned, as was noted in a previous article presented at the 118th Meeting of the American Surgical Association, is that enteric drainage is superior to bladder drainage, in that it reduced the high incidence of urinary tract infections and frequent urological complications and eliminated the need for enteric conversion. 17 Nevertheless, we were surprised to see that in the present series the survival between the 2 techniques was not statistically different long-term. It is estimated that worldwide, 30% to 40% of pancreas transplants, mostly pancreas after kidney (PAK) or pancreas alone, are still using bladder drainage. It is believed that measuring urine amylase levels in these patients aids in early detection of pancreas rejection episodes. Results from our own center with the use of enteric drainage in solitary pancreas transplants do not support this notion. 24 Measuring urinary amylase can be cumbersome for patients and is not specific for rejection. Hence, it is an imperfect monitoring tool. Consequently, it has been our preference to assure the diagnosis of pancreas rejection with graft biopsy whenever possible. 25 Quality of life is better and surgical complications are lower in the enteric drainage group, and most recently, omission of a nasogastric tube has been associated with earlier return of bowel function, less discomfort, and shorter length of stay. 11 The fact that more than half of the bladder-drained patients required enteric conversion is sufficient evidence that the complications of bladder drainage are of a significant nature. Enteric conversion needed to be performed as late as 20 years after transplantation. Our observation is that late conversions are associated with a much higher complication rate and should be offered judiciously, and if performed, use of Roux-en-Y diversion is recommended.
It is difficult to make definitive statements regarding the superiority of one immunosuppressive regimen over others based on this series. With the current regimen of basiliximab induction followed by maintenance with tacrolimus, Myfortic and prednisone, acute rejection episodes have fallen below 10% within the first year post-transplant.
The most important observation from this experience is the unexpectedly high-patient survival in SPK recipients. Patient survival in SPK exceeds even that of living donor recipients who received transplants from well-matched, younger donors, and despite the absence of significant cold ischemia time, fewer surgical complications, and fewer episodes of acute rejection in the living kidney donor recipients. This observation is in contrast to the findings of Young et al 26 and needs to be tempered by the lack of a controlled trial comparing living donation versus SPK, since patient selection may be biased toward SPK. Although it can be argued that this may be an unfair comparison, it is clear that SPK is far superior to deceased donor kidney transplantation for appropriate candidates. Despite the improved patient survival, the major cause of graft loss for all transplant patients in this series is death with function. In the absence of conclusive evidence that SPK recipients have a survival benefit from the pancreas transplant, it is tempting to speculate that improved metabolic control contributes to improved long-term survival.
Cardiovascular morbidity is an important contributor to overall patient outcomes. It should be noted that cardiac interventions before transplantation in this series were low possibly reflecting a low overall cardiac risk profile of these patients. Thus, the low rate of pretransplant interventions may reflect programmatic selection criteria to exclude the highest cardiovascular risk patients or may also in part be due to the nonroutine implementation of coronary angiography screening in the early era of the program. Cardiovascular morbidity and mortality pre-and posttransplant in this patient population will be analyzed in more detail in a follow-up study.
Choosing the appropriate therapy for a type 1 diabetic recipient with kidney failure is an important consideration for patient selection in every pancreas transplant program. The principles and guidelines at our center have been "the potential benefit of the SPK transplant has to outweigh the increased surgical risk." Therefore, it makes little sense to transplant patients with a short life expectancy or patients with such advanced complications that normalization of blood glucose control and insulin independence becomes minor issues. One of the most frequently asked questions by patients and families as well as by referring physicians relates to the choice between SPK and kidney transplantation alone, and if a live donor 
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One Thousand SPK Transplants at a Single Center is available, between live donor kidney and SPK. The advice to the patient must be individualized and is also dependent in large part on regional waiting times for an SPK. It should also take into consideration the relative benefits of reversing uremia versus reversing diabetes in a particular patient. For example, if the patient has a well-matched young live donor and does not have poor glucometabolic lability including hypoglycemic unawareness, a live donor kidney is a good choice. Advantages include no waiting time, pre-emptive transplantation if referred early, and surgery which can be performed electively and with a low complication rate. The degree of secondary diabetic complications or the fear of developing secondary complications should not be a primary factor in the decision-making algorithm. Despite numerous reports of improvement in secondary diabetic complications after SPK, we have not observed a significant change in retinopathy in a careful, blinded study, 27 nor are the reports of cardiac 28 or vascular improvement 29 sufficiently controlled to be conclusive. The only possible exception is severe peripheral and autonomic neuropathy. We have indeed seen patients whose neuropathy either greatly improved or even disappeared within months of an SPK transplant. However, like other series, we did not control for the effect of the kidney alone, and therefore, improvements in neuropathy could be entirely or partly due to restoration of normal renal function (uremic neuropathy).
However, a patient with substantial difficulties controlling blood glucose associated with frequent ketotic or hypoglycemic episodes without awareness resulting in life threatening injuries or poor quality of life, or allergies to various insulin preparations, are candidates for SPK even when a live donor is available.
Of equal or even more importance is the waiting time at the center at which the patient is listed. Wait times, depending on blood type, can range from a few months to 5 years or longer (SRTR data, available at: www.ustransplant.org). Given the high mortality of uremic diabetic patients, if the wait time for an SPK is expected to be long and a live donor is available, it is advisable to use a live donor. At the University of Wisconsin-Madison, the wait time for a blood type A SPK is just a few months. Therefore, SPK transplantation can be recommended. In contrast, there are several major centers where the wait times exceed 5 years for blood type O SPK. At these centers, live donor or even deceased donor transplantation might save life years. At our center, we compared the survival of type 1 diabetic patients receiving various types of transplants. SPK recipients have an expected 20-year survival of 56.8%, whereas it is 32.8% for recipients of a live donor kidney, and 14.7% for recipients of a deceased donor kidney.
Many patients that have already received a kidney transplant alone in the past and have stable kidney allograft function are candidates for a PAK transplant. For uremic diabetic patients, the merits of pancreas after living donor kidney versus SPK transplant have been discussed. Excellent long-term patient survival of PAK transplants has been reported by us and others, 30 -32 and kidney function can be preserved in the majority of cases. 31, 33 Despite excellent success with PAK transplants in the modern immunosuppressive era, we continue to favor SPK as a first option if the waiting time for SPK is anticipated to be relatively short and in the absence of an HLA identical living donor. Also factoring into the decision is perceived risk as a result of the presence of complications of hypoglycemia and the urgency of restoring glucometabolic control.
There are significant limitations of this observational study. It is an uncontrolled experience of 1000 patients followed for over 20 years. There has been an evolution in the patient selection criteria, donor criteria, and significant changes in immunosuppressive therapy during this time period. Nevertheless, the patients have been followed in the same transplant center with nearly complete followup, and it is unlikely that a similar study in long-term survival in SPK patients will be reported. In addition, the living donor and deceased donor recipients received the same posttransplant follow-up as those receiving SPK, including aggressive cardiovascular risk reduction and screening for cardiovascular disease. The patient survival results suggest that the treatment of choice for an appropriate type 1 diabetic recipient is an SPK transplant.
Discussions
DR. DAVID E. R. SUTHERLAND (MINNEAPOLIS, MINNESOTA): As you point out, pancreas transplants began with Lillehei and Kelly at the University of Minnesota in the 1960s, but the results were not good leading to a virtual hiatus by the early 1970s. The revival of pancreas transplantation in the late 1970s and early 1980s, at least in the United States, was centered at 3 institutions in the Midwest-the University of Minnesota, the University of Iowa under the leadership of Dr. Robb Corry, and with you and your team at the University of Wisconsin. Although we have benefited from each other's experience over the years, there are some differences. We have now done over 2000 pancreas transplants at Minnesota with an emphasis on solitary pancreas transplants, particularly in our first 1000, as reported at the American Surgical Association annual meeting in 2000. 1 Beginning in 1978, we gave emphasis to solitary pancreas transplants-pancreas alone (PTA) and pancreas after kidney (PAK)-and not until 1986 did we give equal consideration to simultaneous pancreas-kidney transplantation (SPK). Even so, because we are in a multicenter Organ Procurement Organization (OPO) where not all centers have a pancreas transplant program, allocation of kidneys for SPK candidates, for the most part, followed the kidney allocation algorithm, making it difficult to preempt dialysis with a SPK, unlike Wisconsin where, with a single center OPO, SPK transplants could be given priority, allowing you to preempt dialysis in more than one-third of SPK recipients. We could only preempt dialysis in our uremic diabetic patients by transplanting a living donor (LD) kidney, and thus, for this group the choices were an SPK with the LD giving both organs, as presented more than 10 years ago to the American Surgical Association, 2 adding a DD pancreas transplant if 1 fortuitously became available on the day of a scheduled LD kidney transplant; doing an LD kidney on the day a DD pancreas became available, and hoping the wait time was short; or doing a DD PAK after the LD PAK. As most LDs of a kidney needed a fixed date for work or other reasons, the majority of our uremic patients with diabetes, who received a LD for the kidney, opted for a DD PAK and as a result the ratio of PAK to SPK transplants is about 2:1, while nationally the ratio is just the opposite.
Therefore, even for uremic patients with severe diabetic management problems, such as hypoglycemic unawareness, and for whom a pancreas transplant is particularly beneficial, we encourage preemption of dialysis by a LD kidney if available, plus a simultaneous LD or DD pancreas if possible; but most will get a LD kidney alone followed by a DD PAK. Although the latter entails 2 operations, with this approach at our center the time from presentation to actually receiving the PAK (and thus both organs) is shorter than for those who have no LD for a kidney and must wait for a DD SPK. I would like to ask Dr. Sollinger about the Wisconsin experience with PAK transplants. Obviously the incentive to perform sequential LD KTA and DD PAK is lower in your center than ours since the waiting times for a SPK in your OPO are shorter. Short enough to allow you to preempt dialysis in a high percentage of candidates. Nationwide, the mortality rate waiting for a SPK is 25% at 2 years; the patients on our wait list would rarely receive a SPK within that time, while at yours many would.
We also found that when we perform a PAK and follow patients long term, their kidney function is actually better than in those who received a LD kidney alone. 3 You showed that long-term patient survival was actually better in your SPK recipients than in diabetic recipients of a LD kidney alone, raising the possibility that patient survival may be improved by adding a pancreas.
In Minnesota in our first 1000 pancreas transplants (42% SPK, 32% PAK, 25% PTA), completed between 1978 and 2000, patient survival rates were slightly higher in the SPK than PAK category (79% and 76% at 5 years, 82% for PTA); but in the second 1000 (29% SPK, 42% PAK, 29% PTA) patient survival rates were slightly higher in PAK than SPK recipients (83% and 80% at 5 years; 90% in PTA). Nearly 3-quarters of our PAK recipients received their kidney from a LD, allowing dialysis to be preempted as well as reducing the wait time mortality over that which occurs in SPK candidates and that does not appear in your or our transplant statistics as presented today.
In Minnesota we have not used coronary artery disease as exclusion criteria for pancreas transplants, including in the SPK category. As long as the coronary lesions are correctable by bypass, angioplasty or stenting, we will perform a pancreas transplant. In our first 1000 pancreas transplants, 18% of the uremic patients with diabetes (SPK or PAK) received coronary artery intervention therapy before the transplant; in our second 1000, 65% had such intervention, not because we were more aggressive, but because the proportion of patients with diabetes with coronary artery risk factors increased in our referral population, a change in demographics that was absolutely astonishing to us. We think the change in demographics occurred because of our willingness to perform pancreas transplants in patients with correctable coronary artery disease, producing a bias in the referral patterns based on patient comorbidities. I notice that in the latter part of your series of 1000 SPK
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One Thousand SPK Transplants at a Single Center transplants, you accepted patients with correctable coronary artery disease. I gather that the incidence of pretransplant coronary artery intervention in the Wisconsin SPK recipients was about 3.5%, which is relatively low compared with the incidence in our center. I also noted that your pancreas graft technical failure rate is very, very low, for which you are to be congratulated. Your thrombosis rate is only 3.5%, which is much lower than any other series, and you do it without heparin, thus minimizing bleeding complications as well, a fantastic achievement. We have not been able to achieve such a low rate of thrombosis, and I would like you to address the technical details that contribute to low or high rates of thrombosis Finally, I ask what you see as the future of beta cell replacement therapy, not only for SPK, PAK, or PTA transplants, but also for patients with diabetes in general, with or without complications?
DR. HANS W. SOLLINGER (MADISON, WISCONSIN): I want to come to the core of your question. Is there a difference in patient selection between your center and our center? Obviously, as you already pointed out, we have the luxury of a single OPO, and as a result, our wait times for SPK are shorter, and we can therefore offer pre-emptive transplantation and shorter wait times than at other centers. As far as patient selection, clearly at the beginning of our programs, none of us knew whether pancreas transplantation in combination with a kidney would prolong the life of a diabetic patient. For this reason, we selected low-risk patients because we wanted to avoid a high early morbidity, thus giving us a chance to test over many years or even decades a potential positive influence of the pancreatic graft. A patient with a short life expectancy to start with would not allow us to get these answers. Now that we provided the answer, and I think this article is very strong evidence for the life-prolonging effect of a pancreas, risk factors for our patients have increased. Clearly, pancreas after kidney transplantation and pancreas transplantation alone are options that provide increasingly better results in both of our centers. Your as-yet unpublished report on better kidney function after PAK will be met with interest, and perhaps opposing data, by others.
DR. RAINER W. G. GRUESSNER (TUCSON, ARIZONA): With regard to your data, I take issue with the fact that you only consider low-risk diabetic recipients for pancreas transplants. Given the experience in Minnesota and at other centers, pancreas transplants, particularly in high-risk recipients, are no longer just life-enhancing but rather life-saving. The 4-year mortality rate on the wait list for a combined pancreas-kidney transplant now approaches 50%, a fact often overlooked even by transplant surgeons. I also believe that, because of the scarcity of deceased donor kidneys, the future of pancreas transplantation is not in combined procedures (ie, simultaneous pancreas-kidney transplants). Unlike in your OPO, we have a national problem: the kidney still does not follow the pancreas in most OPOs. As the current chair of the United Network for Organ Sharing pancreas and islet committee, I am keenly aware of the difficulty in making such a national change (ie, from the pancreas following the kidney to, instead, the kidney following the pancreas). My first question to you, therefore, is, "do you think that pancreas after kidney transplants or pancreas transplants alone, even before the development of diabetic nephropathy, will be an alternative to simultaneous pancreas-kidney transplants in the future?" As we do more living related kidney transplants, more of those kidney recipients eventually will be candidates for a subsequent pancreas transplant. If so, I have a second question "since you introduced the bladder drainage technique, do you think it still has a place in these pancreas after kidney transplants, where we cannot use the serum creatinine level as a harbinger of rejection because the kidney and the pancreas are from different donors?" DR. HANS W. SOLLINGER (MADISON, WISCONSIN): As I said in response to Dr. Sutherland's question, we in Madison can offer more SPKs than other centers, and I fully understand why you and Dr. Sutherland must perform more PAKs than we do. The question is does a patient with a well-functioning kidney experience a survival benefit when a pancreas transplant is added? Dr. Sutherland promised us data showing that renal function improves after pancreas transplantation; however, as you know, others have already published data to the contrary, and our own data suggest patients with poor renal function are not great candidates for PAK. Finally, getting back to Dr. Sutherland's last question regarding future therapies, I know that he and many others, including our own laboratory, are closing in on a cure for diabetes that does not require pancreas transplantation.
DR. LLOYD E. RATNER (NEW YORK, NEW YORK): My first question is, with increasing rates of obesity, particularly long term, how many of your patients convert from a type I diabetic to a type II diabetic, and how do you mitigate against that? Second, we all know that the procurement of the pancreas is very important, do you take many imported pancreases, how do you gauge for the quality of the pancreas, and who is procuring it before you receiving it? DR. HANS W. SOLLINGER (MADISON, WISCONSIN): We have not studied the conversion from type 1 to type 2, but given the dramatic weight gain in about 10% of our patients, I believe the incidence is in this range. Second, low surgical complication rates are, of course, in part related to the quality of organ procurement. I would guess this is truer for the pancreas than for any other organ. We in Wisconsin are very fortunate to have had essentially the same team for many years, and almost all the grafts we transplanted were procured by our group. In the first 300, I was personally the procurement surgeon. This is clearly an advantage when it comes to surgical complications. Furthermore, only 3 surgeons (H.W.S., J.S.O., Y.T.B.) performed almost all the implant operations. This assured a high degree of standardization and thus, a low complication rate.
